The first group will receive a placebo. The second group will receive a spiritual chakra treatment designed to correct electrochemical imbalances within the body. The third group will receive medication to treat psychosis. The specific medication does not matter and therefore will not be specified. The dose will be the same for each patient and therefore will be monitored to determine whether dosage is sufficient.
Therefore, the measurements will track each participant and determine which treatment is most effective given the parameters of the study. The placebo group is expected to see no difference, other than perhaps unrelated psychological improvement which will be tracked and recorded as standard error or standard margin of the error estimate. The second group will undergo a physical treatment of chakra adjustment to maximize the flow of energy throughout the body and remedy the physiological response. The treatment will be administered once per day over a course of 3 years. Throughout the process and at the end of the three-month process, the individual will be reassessed regarding the prognosis data as reported.
The third group will receive the medication via oral treatment as administered and recommended by a psychiatric doctor as authorized by the Internal Review Board (IRB). The time frame of the treatment will be exact to the chakra treatment. The improvement of the volunteer subject will be tracked over the course of the treatment and will be benchmarked against the data from groups one and two. Group one, the placebo group, is the control group.
The experimental design is central to the administration of the three groups of volunteer participants. The MRI will reveal whether a volunteer is going to be a patient. Once admitted into the study, each volunteer must fill out a disclaimer form with regard to understanding the procedures that will be undertaken under the experiment as determined by the Internal Review Board (IRB). This is a single blind study so the volunteer is unaware of the treatment however the administrator and doctor are aware of the treatment used and the subject administered.
The procedure of administration is to categorize each volunteer into a group to where administration of the treatment or placebo occurs. The administration of the group two treatment is to be performed by a chakra specialist that understands how the flow of chi throughout the body can become imbalanced and render an abnormal psychological response. The activity is to be performed within the research center within a controlled environment where measurements and tracking of results may occur more effectively. The goal is to ensure internal and external validity throughout the process.
The placebo group is to be administered a pill that resembled a known anti-psychotic medication. The actual medication again is unimportant however what is important is the look and feel of the pill as well as the fact that inert ingredients are used. The placebo group will be tracked via the same methodology as the second and third groups. Each placebo is administered at the research facility and the same standard methods of measuring and tracking are applied to these volunteers as the recipients of the non-placebo remedy, which is the true remedy.
The statistical test to be conducted is the hypothesis test and the correlation of coefficient. The hypothesis test seeks to determine if there is sufficient evidence to reject the null hypothesis, which is the hypothesis that suggests there is no change in the data. Additionally, each hypothesis test is tested at a given level of alpha, which is the level of confidence to which a research can be sure that the data falls within a given range of the standard curve. An alpha of .01 suggests that a researcher can be sure that 99% of the time the null hypothesis can be rejected, however there is a chance for Type I error which is accepting a false hypothesis, which statistically will happen .01% of the time.
The correlation coefficient is the percentage of the data that can be explained away by the data itself. The unexplained percentage is equal to 1-correlcoeff. Together, the results can describe whether the data has statistically proven to support the hypothesis or whether to not support the hypothesis. The results are essentially binary, to where the end of the study each volunteer will render a response with regard as to whether the treatment has worked or has not worked. Additionally, each volunteer will undergo an MRI scan to determine if any volumetric change to the hippocampus has occurred.
The questions to be asked are as follows
Is there a difference between the sample mean and population mean under the standard normal curve for the chakra treatment? H0 does not equal H1
Is there a difference between the sample mean and the population mean under the standard normal curve for the placebo treatment? H0 does not equal H1
Is there a difference between the population mean and the sample mean with under the standard normal curve for the anti-psychotic medication treatment?
The first group received the placebo. N=3000 of the test subjects, 279 of the subjects stated there was no difference between their mental status before the treatment and after the treatment. Estimation of the means indicates that the data provided enough evidence at the 95% confidence level to where there was not sufficient evidence to reject the null hypothesis.
The second test group. N=3000 received the chakra treatment. 2548 reported to have lessened the degree of their bipolar disorder. Estimation of the means indicates that there was sufficient evidence to accept the null hypothesis at the 95% confidence level and believe that there is a difference in the method used to treat bipolar disorder as effective enough to warrant further study on the subject of chakra treatment as a means to address bipolar disorder.
The third test group. N=3000 received the medication treatment. 2642 reported to have lessened the degree of their bipolar disorder. Estimation of the means indicates that there was sufficient evidence to accept the null hypothesis at the 95% confidence level and believe that there is a difference in the method used to treat bipolar disorder to the point of warranting further evidence and study on the subject of anti-psychotic medication as a means to mitigate the neurological effect of bipolar disorder.
The placebo or control group effect determined that the population should have some level of effect from the non-control-based placebo treatment. We did see that the chakra treatment provided a remedy almost as strong in terms of the effecting mood as the anti-psychotic medication. This is to indicate that indeed there is likely a link between the body's electrical and neurological conductivity as a function of interaction between the synapse and axons within the brain and the flow of electrical impulses throughout the body and through all six chakra points.
Hall, J., Whalley, H.C., Marwick, K., McKirdy, J., Sussmann, J., Romaniuk, L., (2010). Hippocampal function in schizophrenia and bipolar disorder. Psychological Medicine, 40(5), 761-761-70. doi:10.1017/S0033291709991000
Kinsella, Caroline and Kinsella, Connor Introducing Mental Health: A Practical Guide (London: Jessica Kingsley, (2006)
Kutscher M., Attwood M.L., Wolff R.R. Kids in the Syndrome Mix of ADHD, LD, Asperger's, Tourette's, Bipolar, and More!: The one stop guide for parents, teachers, and other professionals. Philadelphia Kingsley Publishing (2005)
Martinez-Aran, A., Vieta, E., Colom, F., Torrent, C., Reinares, M., Goikolea, J.M., . . . . (2005). Do cognitive complaints in euthymic bipolar patients reflect objective cognitive impairment? Psychotherapy and Psychosomatics, 74(5), 295-295-302. Retrieved from http://search.proquest.com/docview/235461846?accountid=13044
McDougall, T. (2009). Nursing children and adolescents with bipolar disorder: Assessment, diagnosis, treatment, and management. Journal of Child and Adolescent Psychiatric Nursing, 22(1), 33-33-9. Retrieved fromhttp://search.proquest.com/docview/232965904?accountid=13044
Sachs, G.S., Nierenberg, A.A., Calabrese, J.R., Marangell, L.B., Wisniewski, S.R., Gyulai, L., . . . . (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. The New England Journal of Medicine, 356(17), 1711-1711-22. doi:10.1056/NEJMoa064135
Sanchez-moreno, J., Martinez-aran, A., Tabares-seisdedos, R., Torrent, C., Vieta, E., & Ayuso-mateos, J. (2009). Functioning and disability in bipolar disorder: An extensive review. Psychotherapy and Psychosomatics, 78(5), 285-285-97. Retrieved from http://search.proquest.com/docview/235477611?accountid=13044
Steinkuller, Andrea and Rheineck, Jane E. "A Review of…